BR9609883A - Compound having inhibitory effect on proteinase and pharmaceutical composition and process to treat diseases related to inappropriate or unregulated collagen production - Google Patents

Compound having inhibitory effect on proteinase and pharmaceutical composition and process to treat diseases related to inappropriate or unregulated collagen production

Info

Publication number
BR9609883A
BR9609883A BR9609883A BR9609883A BR9609883A BR 9609883 A BR9609883 A BR 9609883A BR 9609883 A BR9609883 A BR 9609883A BR 9609883 A BR9609883 A BR 9609883A BR 9609883 A BR9609883 A BR 9609883A
Authority
BR
Brazil
Prior art keywords
proteinase
inappropriate
compound
pharmaceutical composition
inhibitory effect
Prior art date
Application number
BR9609883A
Other languages
Portuguese (pt)
Inventor
Mitch Brenner
Wen-Bin Ho
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of BR9609883A publication Critical patent/BR9609883A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9609883A 1995-08-08 1996-08-08 Compound having inhibitory effect on proteinase and pharmaceutical composition and process to treat diseases related to inappropriate or unregulated collagen production BR9609883A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US203895P 1995-08-08 1995-08-08
US60120396A 1996-02-14 1996-02-14
US60918796A 1996-03-01 1996-03-01
PCT/US1996/012876 WO1997005865A1 (en) 1995-08-08 1996-08-08 C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen

Publications (1)

Publication Number Publication Date
BR9609883A true BR9609883A (en) 1999-03-23

Family

ID=27357060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609883A BR9609883A (en) 1995-08-08 1996-08-08 Compound having inhibitory effect on proteinase and pharmaceutical composition and process to treat diseases related to inappropriate or unregulated collagen production

Country Status (9)

Country Link
EP (1) EP0845987A4 (en)
JP (1) JPH11511137A (en)
KR (1) KR19990036271A (en)
CN (1) CN1198096A (en)
AU (1) AU6951296A (en)
BR (1) BR9609883A (en)
CA (1) CA2229098A1 (en)
MX (1) MX9801093A (en)
WO (1) WO1997005865A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0871710A4 (en) * 1995-08-08 2001-03-07 Univ Jefferson Recombinant c-proteinase and processes, methods and uses thereof
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2260859A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
PL331895A1 (en) * 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
US6037139A (en) * 1997-06-03 2000-03-14 Wisconsin Alumni Research Foundation System for assaying modulators of procollagen maturation
EP1398027B1 (en) 1997-07-22 2007-01-10 Shionogi & Co., Ltd. Use of matrix metalloproteinase inhibitors for treating or preventing glomerulopathy
WO1999006340A2 (en) * 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6107337A (en) * 1998-08-06 2000-08-22 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
JP2002531576A (en) 1998-12-10 2002-09-24 エフ.ホフマン−ラ ロシュ アーゲー Procollagen C-proteinase inhibitor
RU2232751C2 (en) * 1998-12-22 2004-07-20 Ф.Хоффманн-Ля Рош Аг Derivatives of sulfonamides and pharmaceutical composition
US6492394B1 (en) 1998-12-22 2002-12-10 Syntex (U.S.A.) Llc Sulfonamide hydroxamates
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
BR0008716A (en) 1999-03-03 2002-09-24 Procter & Gamble Metalloprotease inhibitors containing alkenyl or alkynyl
SK12462001A3 (en) 1999-03-03 2002-04-04 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
US6462063B1 (en) 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2003101382A2 (en) * 2002-05-29 2003-12-11 Merck & Co., Inc. Compounds useful in the treatment of anthrax and inhibiting lethal factor
AU2003291867A1 (en) * 2002-12-03 2004-06-23 Biomep Inc. Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
WO2005061443A2 (en) * 2003-12-19 2005-07-07 Basf Aktiengesellschaft Benzoyl-substituted phenylalanine amides
EP1747212A4 (en) 2004-05-11 2009-03-25 Merck & Co Inc Process for making n-sulfonated-amino acid derivatives
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US7939505B2 (en) 2007-05-04 2011-05-10 Marina Biotech, Inc. Amino acid lipids and uses thereof
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
JP7189369B2 (en) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド Compounds for inhibition of alpha4beta7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP7192139B2 (en) 2018-10-30 2022-12-19 ギリアード サイエンシーズ, インコーポレイテッド Quinoline derivatives as α4β7 integrin inhibitors
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4687841A (en) * 1985-10-18 1987-08-18 Monsanto Company Peptide hydroxamic acid derivatives
US4925868A (en) * 1986-08-29 1990-05-15 Takeda Chemical Industries, Ltd. 4-Hydroxy-3-pyrrolin-2-ones and treatment of circulatory disorders therewith
US5292926A (en) * 1988-01-25 1994-03-08 Santen Pharmaceutical Co., Ltd. Cysteine derivatives
FR2626882B1 (en) * 1988-02-08 1991-11-08 Ire Celltarg Sa VINCA DERIVATIVE CONJUGATES COMPRISING A DETERGENT CHAIN IN POSITION C-3
NZ229004A (en) * 1988-05-19 1993-09-27 Immunobiology Res Inst Inc Tetrapeptides having t cell helper acitivity
FR2655339B2 (en) * 1989-04-19 1992-04-10 Medgenix Group Sa COMPOUNDS AND COMPLEXES USEFUL IN PARTICULAR IN MEDICAL IMAGING.
GB9008078D0 (en) * 1990-04-10 1990-06-06 Beecham Group Plc Novel compounds
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
US5237057A (en) * 1992-04-06 1993-08-17 Biosite Diagnostics, Inc. Tetrahydrocannabinol derivatives and protein and polypeptide tetrahydrocannabinol derivative conjugates and labels
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5393902A (en) * 1994-04-26 1995-02-28 Lever Brothers Company, Division Of Conopco, Inc. Process for the preparation of bis(amidocarboxylic acids)

Also Published As

Publication number Publication date
AU6951296A (en) 1997-03-05
KR19990036271A (en) 1999-05-25
JPH11511137A (en) 1999-09-28
CN1198096A (en) 1998-11-04
EP0845987A1 (en) 1998-06-10
CA2229098A1 (en) 1997-02-20
EP0845987A4 (en) 2000-05-24
MX9801093A (en) 1998-04-30
WO1997005865A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
BR9609883A (en) Compound having inhibitory effect on proteinase and pharmaceutical composition and process to treat diseases related to inappropriate or unregulated collagen production
BR9607157A (en) Composition of dandruff shampoo and process to produce the same
BR9606722B1 (en) Low shrink refractory fiberglass and process for its production
BR9503638A (en) Compound process for its production and pharmaceutical formulation
BR9403442A (en) Silanes, process for their production and application of said silanes
BR9612135A (en) Process taxoids for their preparation and pharmaceutical composition
BR9505051A (en) Compound derived from 2,4-oxazolidinedione process for its production and pharmaceutical composition
PT750907E (en) METHOD FOR THEIR USE AND PROCESS FOR THEIR PREPARATION
BR9611198A (en) Compound preparation process and pharmaceutical composition
BR9603072A (en) Hair treatment agent and process for its preparation
BR9606396A (en) Substituted camptotecin derivatives and process for their preparation
BR9708336A (en) Eprosartan dihydrate and process for its production and formulation
BR9306120A (en) Fiber and process for its production
BR9600285A (en) Process to disable or destroy microorganisms
BR9602337A (en) Compound process for its preparation uses the same process for treating arrhythmias and medication
PT1015421E (en) NEW PHENYLAMIDINE DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES
BR9607413A (en) Process for the production of pentafluorethane and tetrafluorochloroethane
BR9603228A (en) Process for making tanned leather waterproof and aqueous composition
BR9603441A (en) Brush and process for your production
BR9601467A (en) Use of at least a cgrp antagonist pharmaceutical and / or dermatological cosmetic composition and cosmetic treatment process
PT827693E (en) PROCESS OF MANUFACTURE AND PRODUCT COMPOSED GUARNECIDO
BR9605038A (en) Process to control unwanted vegetation compound and herbicidal composition
BR9300034A (en) COMPOUND, PROCESS FOR ITS PRODUCTION AND HEALING COMPOSITION
BR9401490A (en) Shampoo composition and process for its production
PT862545E (en) COMPOSITION PESTICIDES AND PROCESS FOR THEIR PREPARATION

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law